Dataset Information

Head and Neck Cancers, Version 1.2015.

ABSTRACT: These NCCN Guidelines Insights focus on recent updates to the 2015 NCCN Guidelines for Head and Neck (H&N) Cancers. These Insights describe the different types of particle therapy that may be used to treat H&N cancers, in contrast to traditional radiation therapy (RT) with photons (x-ray). Research is ongoing regarding the different types of particle therapy, including protons and carbon ions, with the goals of reducing the long-term side effects from RT and improving the therapeutic index. For the 2015 update, the NCCN H&N Cancers Panel agreed to delete recommendations for neutron therapy for salivary gland cancers, because of its limited availability, which has decreased over the past 2 decades; the small number of patients in the United States who currently receive this treatment; and concerns that the toxicity of neutron therapy may offset potential disease control advantages.

SUBMITTER: Pfister DG

PROVIDER: S-EPMC4976490 | biostudies-other | 2015 Jul

REPOSITORIES: biostudies-other

ACCESS DATA

Publications

Head and Neck Cancers, Version 1.2015.

Pfister David G DG Spencer Sharon S Brizel David M DM Burtness Barbara B Busse Paul M PM Caudell Jimmy J JJ Cmelak Anthony J AJ Colevas A Dimitrios AD Dunphy Frank F Eisele David W DW Foote Robert L RL Gilbert Jill J Gillison Maura L ML Haddad Robert I RI Haughey Bruce H BH Hicks Wesley L WL Hitchcock Ying J YJ Jimeno Antonio A Kies Merrill S MS Lydiatt William M WM Maghami Ellie E McCaffrey Thomas T Mell Loren K LK Mittal Bharat B BB Pinto Harlan A HA Ridge John A JA Rodriguez Cristina P CP Samant Sandeep S Shah Jatin P JP Weber Randal S RS Wolf Gregory T GT Worden Frank F Yom Sue S SS McMillian Nicole N Hughes Miranda M

Journal of the National Comprehensive Cancer Network : JNCCN 20150701 7

These NCCN Guidelines Insights focus on recent updates to the 2015 NCCN Guidelines for Head and Neck (H&N) Cancers. These Insights describe the different types of particle therapy that may be used to treat H&N cancers, in contrast to traditional radiation therapy (RT) with photons (x-ray). Research is ongoing regarding the different types of particle therapy, including protons and carbon ions, with the goals of reducing the long-term side effects from RT and improving the therapeutic index. For ...[more]

PMID: 26150579

Similar Datasets

Project description:BackgroundHepatitis C virus (HCV) infection is associated with hepatocellular carcinoma and non-Hodgkin's lymphoma. In 2009, MD Anderson established the first US clinic for treating HCV-infected cancer patients, where we observed an unexpectedly large number of patients with head and neck cancers (HNCs). We sought to determine whether HCV is associated with HNCs.MethodsIn this case-control study, medical records of cancer patients tested for HCV antibodies at our center from 2004 through 2014 were identified. Case subjects had new-onset primary oropharyngeal or nonoropharyngeal (oral cavity, nasopharynx, hypopharynx, or larynx) HNCs. Control subjects had smoking-associated (lung, esophagus, or urinary bladder) cancers. Biopsy reports of oropharyngeal cancers tested for human papillomavirus (HPV) were reviewed. Patients with lymphoma were excluded. Multivariable logistic regression models were constructed. All statistical tests were two-sided.ResultsOf 34 545 cancer patients tested for HCV antibodies, 409 case subjects (164 oropharyngeal and 245 nonoropharyngeal) and 694 control subjects (378 lung, 168 esophagus, and 148 urinary bladder) were studied. The prevalence of HCV seropositivity was higher in oropharyngeal cancer patients (14.0%, 95% confidence interval [CI] = 8.7% to 19.4%, vs 6.5%, 95% CI = 4.6% to 8.3%), particularly HPV-positive oropharyngeal cancer patients (16.9%, 95% CI = 8.7% to 24.9%, vs 6.5%, 95% CI = 4.6% to 8.3%), and nonoropharyngeal HNC patients (20.0%, 95% CI = 14.9% to 25.0%, vs 6.5%, 95% CI = 4.6% to 8.3%) than in control subjects. Adjusted models showed a statistically significant association of HCV seropositivity with nonoropharyngeal (except nasopharyngeal) HNCs (odds ratio [OR] = 2.85, 95% CI = 1.38 to 5.88) and HPV-positive oropharyngeal cancers (OR = 2.97, 95% CI = 1.31 to 6.76).ConclusionsHCV is associated with nonoropharyngeal (except nasopharyngeal) and HPV-positive oropharyngeal HNCs. Further studies are required to explore the possible interaction between HCV and HPV, and the association between HCV and other HPV-related malignancies.

Dataset Information

Head and Neck Cancers, Version 1.2015.

Publications

Head and Neck Cancers, Version 1.2015.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets